A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Launched by ELI LILLY AND COMPANY ยท
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medicine called orforglipron to see if it can help people who are overweight or have obesity and also have knee osteoarthritis, which is a condition that causes pain and stiffness in the knee joint. The goal is to find out how well this medicine works and how safe it is for these patients.
The study is looking for adults aged 65 to 74 of any gender who have knee osteoarthritis and are overweight or obese. If you join the study, you can expect to be part of a program that lasts about 74 weeks (around a year and a half), during which the researchers will monitor your health and knee pain while you take the medicine. This study is not yet open for new participants, but it aims to understand if orforglipron could be a helpful treatment option for people with knee osteoarthritis and weight challenges.
Gender
ALL
Eligibility criteria
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported